- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03173859
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients (AERA)
A Randomized Phase II Study to Investigate the Efficacy of Rotations Between Abiraterone Acetate and Apalutamide Versus Sequential Administration in Chemo-naïve Metastatic Castration Resistant Prostate Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, randomized phase II study to investigate the feasibility of alternating cycles of treatment with abiraterone plus prednisone and apalutamide compared to sequential treatment of abiratereone plus prednisone followed by apalutamide. 7 centers in Greece will participate in the study.
The study population consists of adult patients (over 18 years old) with histologically confirmed metastatic prostate adenocarcinoma who have disease progression - as defined by PCWG2 criteria - despite androgen deprivation therapy and who have not received prior therapy for their castration resistant disease.
The purpose of the study is to determine the progression free survival, feasibility and safety profile of the experimental arm compared to standard of care.
In the experimental arm alternating treatment will consist of repeating cycles of 24 weeks of treatment consisting of 12 weeks of abiraterone acetate 1000mg orally qd and prednisone 5mg orally bid, followed by 12 weeks of apalutamide 240 mg per day. There will be no wash out period between cycles.
The comparative arm will be the standard regimen of abiraterone 1000mg orally qd plus prednisone 5mg orally bid until progression, followed thereafter by apalutamide 240mg orally qd until progression.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Age >18 years Histologically confirmed metastatic or advanced prostate cancer adenocarcinoma that has received no treatment for the castration resistant disease and has progressed during treatment with complete androgen blockade (luteinizing hormone releasing hormone agonist or antagonist and an antiandrogen eg. Bicalutamide).
Availability of a representative formalin-fixed, paraffin-embedded tumor specimen (FFPE) that enabled definitive diagnosis of prostate cancer.
Two rising PSA levels >2ng/ml measured 1 week apart during or following the most recent prior therapy for prostate cancer (PCWG2 criteria) or radiographic evidence of disease progression in bone with or without biochemical disease progression on the basis of the PSA value.
Ongoing androgen deprivation, with serum testosterone <50ng/dl ECOG performance status 0-1 at screening Adequate hematologic and organ function within 14 days before the first study treatment (hematologic parameters must be assessed >14 days after a prior transfusion, if any) as defined by
- Hemoglobin >9g/dl
- Neutrophils >1500/μL
- Platelet count >100000/μL
Total bilirubin <1,5xULN with the following exception:
o Patients with known Gilbert syndrome who have serum bilirubin<3xULN
AST and ALT<2,5xULN with the following exception
o Patients with bone-only metastasis may have AST<5xULN, provided that ALT <2,5xULN and total bilirubin <1,5xULN
- Serum albumin >3g/dl
- Serum potassium ≥3.5mmol/L
- Serum creatinine <1,5xULN or creatinine clearance of >50ml/min based on Cockcroft-Gault equation
- Agreement by patient and/or partner to use an effective form of contraception including surgical sterilization, reliable barrier method, birth control pills, contraceptive hormone implants or true abstinence and to continue its use for the duration of the study and for 6 months after the last dose of study treatment.
Exclusion Criteria:
- Small cell or neuroendocrine prostate carcinoma Inability or unwillingness to swallow pills Malabsorption syndrome or other condition that would interfere with enteral absorption Congenital long QT syndrome or QTc>480msec NYHA Class II to IV heart failure or LVEF <50% or ventricular arrhythmia requiring medication Previous therapy for prostate cancer with CYP17 inhibitors including ketoconazole or investigational agents (VMT-VT-464, Orteronel etc) or novel antiandrogens (enzalutamide of OMD-208) for more than 7 days Presence of visceral metastasis History of another invasive cancer within 3 years from screening, with the exception of fully treated cancers with a remote probability of recurrence Duration of previous Androgen Deprivation Therapy <12months Active infection requiring IV antibiotics
Clinically significant cardiovascular disease including the following:
- unstable angina,
- myocardial infarction within 6 months from screening, or
- cerebrovascular accident within 6 months from screening Major surgical procedure within 4 weeks prior to initiation of study treatment Treatment with an investigational agent within 4 weeks prior to initiation of study treatment Unresolved, clinical significant toxicity from prior treatment Hypersensitivity reaction to the active pharmaceutical ingredient or any of the tablet components Any medical condition that restrain the patient to comply with study and follow-up procedures Inability to comply with study and follow up procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Rotational
Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles.
The duration of each cycle is 28 days
|
Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
Other Names:
apalutamide 240mg qD orally
|
ACTIVE_COMPARATOR: Sequential
Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
|
Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
Other Names:
apalutamide 240mg qD orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic progression-free survival
Time Frame: Estimated up to 24 months
|
time until radiographic progression as assessed by PCWG2 criteria
|
Estimated up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: estimated up to 36 months
|
time until death or lost to follow up
|
estimated up to 36 months
|
Time to cytotoxic therapy initiation
Time Frame: Estimated up to 24 months
|
time until the beginning of chemotherapy
|
Estimated up to 24 months
|
Time until PSA progression
Time Frame: Estimated up to 24 months
|
time until PSA progression as defined by PCWG2 criteria
|
Estimated up to 24 months
|
Incidence, nature and severity of AEs
Time Frame: Estimated up to 24 months
|
recording of all AE/SAEs
|
Estimated up to 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported outcomes assessed using the FACT-P and EQ-5D-5L questionnaires
Time Frame: Estimated up to 24 months
|
Differences in FACT-P questionnaires between treatment groups
|
Estimated up to 24 months
|
Number of Circulating Tumor Cells (CTCs) and ARv7 analysis in CTCs from peripheral blood at baseline evaluation, first and second disease progression in Arm 2 and disease progression in Arm 1 (PD1).
Time Frame: Estimated up to 24 months
|
Correlation of CTCs number and ARv7 expression with rPFS and OS in these patients
|
Estimated up to 24 months
|
Patient reported outcomes assessed using the EQ-5D-5L questionnaires
Time Frame: Estimated up to 24 months
|
Differences in EQ-5D-5L questionnaires between treatment groups
|
Estimated up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 70/3/14073
- 2017-000443-41 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms, Castration-Resistant
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingProstatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic NeoplasmsUnited States, Canada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingProstate Cancer | Refractory Cancer | Castration Resistant Prostatic CancerUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedMetastatic Prostate Cancer | Castration Resistant Prostatic CancerUnited States
Clinical Trials on Abiraterone
-
Jiangnan UniversityAffiliated Hospital of Jiangnan UniversityRecruitingCastration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Janssen Research & Development, LLCCompleted
-
Radboud University Medical CenterCompletedProstate CancerNetherlands
-
AstraZenecaParexelCompleted
-
Dana-Farber Cancer InstituteCompleted
-
Kangpu Biopharmaceuticals, Ltd.CompletedCastration-Resistant Prostate CancerUnited States
-
Arvinas Androgen Receptor, Inc.Active, not recruitingProstate Cancer MetastaticCanada, United States, France, United Kingdom
-
Janssen Research & Development, LLCCompleted
-
Cougar Biotechnology, Inc.Completed